<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />

<meta name="viewport" content="width=device-width, initial-scale=1" />

<meta name="author" content="Sung" />


<title>Drug and Oncogene Information</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>

<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
</style>







<style type="text/css">body {
background-color: #fff;
margin: 1em auto;
max-width: 700px;
overflow: visible;
padding-left: 2em;
padding-right: 2em;
font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif;
font-size: 14px;
line-height: 1.35;
}
#TOC {
clear: both;
margin: 0 0 10px 10px;
padding: 4px;
width: 400px;
border: 1px solid #CCCCCC;
border-radius: 5px;
background-color: #f6f6f6;
font-size: 13px;
line-height: 1.3;
}
#TOC .toctitle {
font-weight: bold;
font-size: 15px;
margin-left: 5px;
}
#TOC ul {
padding-left: 40px;
margin-left: -1.5em;
margin-top: 5px;
margin-bottom: 5px;
}
#TOC ul ul {
margin-left: -2em;
}
#TOC li {
line-height: 16px;
}
table {
margin: 1em auto;
border-width: 1px;
border-color: #DDDDDD;
border-style: outset;
border-collapse: collapse;
}
table th {
border-width: 2px;
padding: 5px;
border-style: inset;
}
table td {
border-width: 1px;
border-style: inset;
line-height: 18px;
padding: 5px 5px;
}
table, table th, table td {
border-left-style: none;
border-right-style: none;
}
table thead, table tr.even {
background-color: #f7f7f7;
}
p {
margin: 0.5em 0;
}
blockquote {
background-color: #f6f6f6;
padding: 0.25em 0.75em;
}
hr {
border-style: solid;
border: none;
border-top: 1px solid #777;
margin: 28px 0;
}
dl {
margin-left: 0;
}
dl dd {
margin-bottom: 13px;
margin-left: 13px;
}
dl dt {
font-weight: bold;
}
ul {
margin-top: 0;
}
ul li {
list-style: circle outside;
}
ul ul {
margin-bottom: 0;
}
pre, code {
background-color: #f7f7f7;
border-radius: 3px;
color: #333;
white-space: pre-wrap; 
}
pre {
border-radius: 3px;
margin: 5px 0px 10px 0px;
padding: 10px;
}
pre:not([class]) {
background-color: #f7f7f7;
}
code {
font-family: Consolas, Monaco, 'Courier New', monospace;
font-size: 85%;
}
p > code, li > code {
padding: 2px 0px;
}
div.figure {
text-align: center;
}
img {
background-color: #FFFFFF;
padding: 2px;
border: 1px solid #DDDDDD;
border-radius: 3px;
border: 1px solid #CCCCCC;
margin: 0 5px;
}
h1 {
margin-top: 0;
font-size: 35px;
line-height: 40px;
}
h2 {
border-bottom: 4px solid #f7f7f7;
padding-top: 10px;
padding-bottom: 2px;
font-size: 145%;
}
h3 {
border-bottom: 2px solid #f7f7f7;
padding-top: 10px;
font-size: 120%;
}
h4 {
border-bottom: 1px solid #f7f7f7;
margin-left: 8px;
font-size: 105%;
}
h5, h6 {
border-bottom: 1px solid #ccc;
font-size: 105%;
}
a {
color: #0033dd;
text-decoration: none;
}
a:hover {
color: #6666ff; }
a:visited {
color: #800080; }
a:visited:hover {
color: #BB00BB; }
a[href^="http:"] {
text-decoration: underline; }
a[href^="https:"] {
text-decoration: underline; }

code > span.kw { color: #555; font-weight: bold; } 
code > span.dt { color: #902000; } 
code > span.dv { color: #40a070; } 
code > span.bn { color: #d14; } 
code > span.fl { color: #d14; } 
code > span.ch { color: #d14; } 
code > span.st { color: #d14; } 
code > span.co { color: #888888; font-style: italic; } 
code > span.ot { color: #007020; } 
code > span.al { color: #ff0000; font-weight: bold; } 
code > span.fu { color: #900; font-weight: bold; } 
code > span.er { color: #a61717; background-color: #e3d2d2; } 
</style>




</head>

<body>




<h1 class="title toc-ignore">Drug and Oncogene Information</h1>
<h4 class="author">Sung</h4>


<div id="TOC">
<ul>
<li><a href="#drug-information" id="toc-drug-information">Drug
Information</a></li>
<li><a href="#detailed-functions" id="toc-detailed-functions">Detailed
Functions</a></li>
<li><a href="#combinational-drug-theraphy-expectations" id="toc-combinational-drug-theraphy-expectations">Combinational drug
theraphy expectations</a>
<ul>
<li><a href="#pembrolizumab-keytruda" id="toc-pembrolizumab-keytruda">Pembrolizumab (Keytruda)</a></li>
<li><a href="#nivolumab-opdivo" id="toc-nivolumab-opdivo">Nivolumab
(Opdivo)</a></li>
<li><a href="#pembrolizumab-or-nivolumab-combined-with-dgki" id="toc-pembrolizumab-or-nivolumab-combined-with-dgki">Pembrolizumab or
Nivolumab Combined with DGKi</a></li>
<li><a href="#pembrolizumab-or-nivolumab-combined-with-ds-1062a" id="toc-pembrolizumab-or-nivolumab-combined-with-ds-1062a">Pembrolizumab
or Nivolumab Combined with DS-1062a</a></li>
<li><a href="#pembrolizumab-or-nivolumab-combined-with-tak-676" id="toc-pembrolizumab-or-nivolumab-combined-with-tak-676">Pembrolizumab
or Nivolumab Combined with TAK-676</a></li>
</ul></li>
<li><a href="#ds-1062a" id="toc-ds-1062a">DS-1062a</a>
<ul>
<li><a href="#component-of-ds-1062a" id="toc-component-of-ds-1062a">Component of DS-1062a</a></li>
<li><a href="#datopotamab-deruxtecan-nci-info" id="toc-datopotamab-deruxtecan-nci-info">Datopotamab Deruxtecan (NCI
Info)</a></li>
</ul></li>
</ul>
</div>

<p><br> Update: “2024-06-17”</p>
<p><br><br></p>
<div id="drug-information" class="section level2">
<h2>Drug Information</h2>
<p>This is the list of drugs that I have analyzed testing data of in
DFCI.</p>
<ul>
<li>DGKi<br />
</li>
<li>DS-1062a<br />
</li>
<li>TAK-676<br />
</li>
<li>ADU-S100<br />
</li>
<li>Pembrolizumab<br />
</li>
<li>Nivolumab</li>
</ul>
<table>
<colgroup>
<col width="4%" />
<col width="25%" />
<col width="30%" />
<col width="6%" />
<col width="6%" />
<col width="26%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Drug</strong></th>
<th><strong>Target/Mechanism</strong></th>
<th><strong>Clinical Applications</strong></th>
<th><strong>Development Stage</strong></th>
<th><strong>Company</strong></th>
<th><strong>Sources</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>DGKi</strong></td>
<td>Inhibits diacylglycerol kinase, enhancing T-cell activation and
immune responses by modulating DAG and PA signaling pathways.</td>
<td>Explored for potential application in enhancing the efficacy of
cancer immunotherapies by boosting T-cell functionality.</td>
<td>Preclinical/early clinical trials</td>
<td>Bristol Myers Squibb</td>
<td><a href="https://www.nature.com/articles/s41573-022-0048-9">Nature
Review on DGK inhibitors</a></td>
</tr>
<tr class="even">
<td><strong>DS-1062a</strong></td>
<td>TROP2-targeting antibody-drug conjugate with a cytotoxic
topoisomerase I inhibitor payload (deruxtecan).</td>
<td>Targeted therapy for TROP2-expressing tumors, including non-small
cell lung cancer and triple-negative breast cancer.</td>
<td>Phase II/III clinical trials</td>
<td>Daiichi Sankyo</td>
<td><a href="https://www.daiichisankyo.com/rd/pipeline/oncology/index.html">Daiichi
Sankyo’s Pipeline</a></td>
</tr>
<tr class="odd">
<td><strong>TAK-676</strong></td>
<td>Synthetic cyclic dinucleotide that acts as a STING agonist to
activate the innate immune system.</td>
<td>Enhancing the effectiveness of existing cancer therapies by
promoting immune cell infiltration and activation in tumors.</td>
<td>Phase I/II clinical trials</td>
<td>Takeda Pharmaceuticals</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04144140">ClinicalTrials.gov
Entry for TAK-676</a></td>
</tr>
<tr class="even">
<td><strong>ADU-S100</strong></td>
<td>Synthetic cyclic dinucleotide STING agonist that stimulates type I
interferon and pro-inflammatory cytokine production.</td>
<td>Used in combination with immune checkpoint inhibitors to treat
advanced solid tumors and cutaneous malignancies.</td>
<td>Phase I/II clinical trials</td>
<td>Aduro Biotech, Novartis</td>
<td><a href="https://www.aduro.com/science/cdn-approach/sting-pathway/">Aduro’s
ADU-S100 Information</a></td>
</tr>
</tbody>
</table>
<p><br><br></p>
</div>
<div id="detailed-functions" class="section level2">
<h2>Detailed Functions</h2>
<p><strong>DGKi</strong>:<br />
- DGKi targets diacylglycerol kinase, an enzyme that regulates T-cell
activation by modulating the levels of diacylglycerol (DAG) and
phosphatidic acid (PA) within cells. Inhibition of this enzyme prevents
the conversion of DAG to PA, thereby maintaining DAG levels that are
crucial for downstream signaling events following T-cell receptor
engagement. This mechanism is believed to potentiate the immune response
by enhancing T-cell activation, proliferation, and survival, making it a
valuable target for boosting the effectiveness of T-cell-based cancer
immunotherapies. <br><br> <strong>DS-1062a</strong>:<br />
- DS-1062a is designed to selectively target and kill TROP2-expressing
tumor cells. Its mechanism involves the targeted delivery of a potent
cytotoxic drug directly to the tumor cells, minimizing the impact on
non-targeted cells. This targeted approach allows for higher drug
concentrations at the tumor site, increasing tumor cell death while
reducing systemic toxicity. The ADC mechanism of DS-1062a utilizes the
internalization of the TROP2 antibody bound to its antigen on cancer
cells, followed by the intracellular release of the cytotoxic payload
that induces DNA damage and cell death. <br><br>
<strong>TAK-676</strong>:<br />
- TAK-676 utilizes the STING (Stimulator of Interferon Genes) pathway to
initiate and amplify the immune response against cancer cells. By
activating STING, TAK-676 triggers a cascade of signaling events that
lead to the production of type I interferons and other cytokines, which
enhance the body’s ability to detect and destroy cancer cells. This
activation is crucial for recruiting and activating immune cells,
including T cells and NK cells, into the tumor microenvironment, thereby
improving the overall effectiveness of cancer immunotherapies. <br><br>
<strong>ADU-S100</strong>:<br />
- ADU-S100 works by targeting the STING pathway, which plays a pivotal
role in the innate immune system’s ability to detect and respond to the
presence of tumor-derived or pathogen-derived cytosolic DNA. Activation
of this pathway by ADU-S100 leads to the induction of a strong
inflammatory response that promotes the activation and recruitment of
dendritic cells and T cells, key players in the adaptive immune
response. This mechanism enhances the visibility of tumors to the immune
system and facilitates the establishment of an effective anti-tumor
immune response, especially when used in combination with other
therapies that modulate the immune environment.</p>
<p><br><br><br></p>
</div>
<div id="combinational-drug-theraphy-expectations" class="section level2">
<h2>Combinational drug theraphy expectations</h2>
<div id="pembrolizumab-keytruda" class="section level3">
<h3>Pembrolizumab (Keytruda)</h3>
<p><strong>Mechanism of Action:</strong></p>
<ul>
<li>Pembrolizumab is a humanized monoclonal antibody that targets the
programmed cell death protein 1 (PD-1) receptor on T cells. By binding
to PD-1, pembrolizumab blocks its interaction with its ligands, PD-L1
and PD-L2, which are often overexpressed on cancer cells. This blockade
releases the “brakes” on T cells, enabling them to mount a stronger
immune response against cancer cells.</li>
</ul>
<p><strong>Clinical Applications:</strong></p>
<ul>
<li>Pembrolizumab is approved for the treatment of various cancers,
including melanoma, non-small cell lung cancer (NSCLC), head and neck
squamous cell carcinoma, classical Hodgkin lymphoma, and urothelial
carcinoma, among others. It is also being investigated in clinical
trials for other cancer types.</li>
</ul>
</div>
<div id="nivolumab-opdivo" class="section level3">
<h3>Nivolumab (Opdivo)</h3>
<p><strong>Mechanism of Action:</strong></p>
<ul>
<li>Nivolumab is also a human monoclonal antibody that targets the PD-1
receptor on T cells. Similar to pembrolizumab, it blocks the interaction
between PD-1 and its ligands PD-L1 and PD-L2, enhancing the immune
system’s ability to detect and destroy cancer cells.</li>
</ul>
<p><strong>Clinical Applications:</strong></p>
<ul>
<li>Nivolumab is approved for a variety of cancers, including melanoma,
non-small cell lung cancer (NSCLC), renal cell carcinoma, classical
Hodgkin lymphoma, and head and neck squamous cell carcinoma. It is also
under investigation for other malignancies in clinical trials.</li>
</ul>
</div>
<div id="pembrolizumab-or-nivolumab-combined-with-dgki" class="section level3">
<h3>Pembrolizumab or Nivolumab Combined with DGKi</h3>
<p><strong>Advantages:</strong></p>
<ol style="list-style-type: decimal">
<li><strong>Enhanced T-cell Activation</strong>: DGKi enhances T-cell
activation by modulating DAG and PA signaling pathways. This could
potentially synergize with Pembrolizumab or Nivolumab, which release the
brakes on T-cells by blocking PD-1, leading to a more robust anti-tumor
response.<br />
</li>
<li><strong>Improved Efficacy</strong>: Combining two different
mechanisms to stimulate T-cells could increase the overall efficacy of
the immune response against tumors.</li>
</ol>
<p><strong>Disadvantages:</strong></p>
<ol style="list-style-type: decimal">
<li><strong>Increased Immune-Related Adverse Events (irAEs)</strong>:
Both PD-1 inhibitors and DGKi can enhance immune responses, which might
lead to a higher risk of autoimmune reactions and other immune-related
adverse events.<br />
</li>
<li><strong>Complex Management</strong>: The combination may require
careful monitoring and management of side effects, which could
complicate treatment protocols.</li>
</ol>
</div>
<div id="pembrolizumab-or-nivolumab-combined-with-ds-1062a" class="section level3">
<h3>Pembrolizumab or Nivolumab Combined with DS-1062a</h3>
<p><strong>Advantages:</strong></p>
<ol style="list-style-type: decimal">
<li><strong>Targeted Cytotoxicity</strong>: DS-1062a targets
TROP2-expressing tumors, delivering a cytotoxic payload directly to
cancer cells. When combined with Pembrolizumab or Nivolumab, this
approach could enhance the immune system’s ability to attack cancer
cells while simultaneously delivering a lethal blow to the tumor.<br />
</li>
<li><strong>Broadened Applicability</strong>: This combination could be
effective in TROP2-expressing tumors that may not respond well to PD-1
inhibitors alone.</li>
</ol>
<p><strong>Disadvantages:</strong></p>
<ol style="list-style-type: decimal">
<li><strong>Overlapping Toxicities</strong>: Both treatments can cause
specific side effects, and when combined, there might be an increase in
overlapping toxicities, such as fatigue, nausea, and potential
immune-related issues.<br />
</li>
<li><strong>Treatment Complexity</strong>: Administering an
antibody-drug conjugate (ADC) alongside a PD-1 inhibitor could increase
the complexity of the treatment regimen.</li>
</ol>
</div>
<div id="pembrolizumab-or-nivolumab-combined-with-tak-676" class="section level3">
<h3>Pembrolizumab or Nivolumab Combined with TAK-676</h3>
<p><strong>Advantages:</strong></p>
<ol style="list-style-type: decimal">
<li><strong>Enhanced Immune Activation</strong>: TAK-676, a STING
agonist, activates the innate immune system, leading to increased
production of type I interferons and cytokines. This could enhance the
effectiveness of Pembrolizumab or Nivolumab by further stimulating an
immune response against the tumor.<br />
</li>
<li><strong>Synergistic Effects</strong>: The combination could
potentially lead to a stronger and more sustained anti-tumor response by
activating both the innate and adaptive immune systems.</li>
</ol>
<p><strong>Disadvantages:</strong></p>
<ol style="list-style-type: decimal">
<li><strong>Increased Risk of Inflammation</strong>: Both STING agonists
and PD-1 inhibitors can cause inflammation. Combined use might increase
the risk of severe inflammatory responses, necessitating careful patient
monitoring.<br />
</li>
<li><strong>Potential Redundancy</strong>: There may be cases where the
activation of the immune system by TAK-676 does not significantly add to
the effect already achieved by PD-1 inhibition.</li>
</ol>
<!-- ### Pembrolizumab or Nivolumab Combined with ADU-S100 -->
<!-- **Advantages:** -->
<!-- 1. **Potent Immune Activation**: ADU-S100 activates the STING pathway, leading to robust production of interferons and cytokines that can enhance T-cell responses. Combined with Pembrolizumab or Nivolumab, this could result in a more effective anti-tumor immune response. -->
<!-- 2. **Combination Synergy**: The activation of STING by ADU-S100 can create an immune-stimulatory tumor microenvironment, which, in conjunction with the T-cell activation provided by PD-1 inhibitors, could lead to significant tumor regression. -->
<!-- **Disadvantages:** -->
<!-- 1. **Immune-Related Toxicity**: The combination of STING agonists with PD-1 inhibitors may lead to heightened immune-related toxicities, such as severe autoimmune reactions. -->
<!-- 2. **Management Challenges**: Managing the side effects and monitoring patient responses could be more challenging due to the potent immune activation from both agents. -->
<hr>
</div>
</div>
<div id="ds-1062a" class="section level2">
<h2>DS-1062a</h2>
<div id="component-of-ds-1062a" class="section level3">
<h3>Component of DS-1062a</h3>
<p><strong>TROP2</strong></p>
<ul>
<li>Trophoblast cell surface antigen 2 (TROP2)</li>
<li>aka, tumor-associated calcium signal transducer 2 (TACSTD2), is</li>
<li>a cell surface glycoprotein that acts as a transmembrane transducer
of intracellular (IC) calcium signals.</li>
<li>Trop2 has stem cell-like qualities and regulates cell growth,
transformation, regeneration, and proliferation, which explains why its
overexpression can lead to <strong>tumor progression</strong></li>
<li><a href="https://www.nature.com/articles/s41698-024-00584-z">Paper:
Precision Oncology; April 2024; A new TROP2-targeting antibody-drug
conjugate shows potent antitumor efficacy in breast and lung
cancers</a></li>
</ul>
<p><strong>Dxd</strong></p>
<ul>
<li>Deruxtecan, topoisomerase inhibitor.</li>
<li>Cause DNA damage leading cells to apoptosis.</li>
</ul>
<p><strong>DS-1062a</strong></p>
<ul>
<li>datopotamab deruxtecan.</li>
<li>(TROP2)-targeting antibody drug conjugate with Dxd.</li>
</ul>
</div>
<div id="datopotamab-deruxtecan-nci-info" class="section level3">
<h3>Datopotamab Deruxtecan (NCI Info)</h3>
<ol style="list-style-type: decimal">
<li><strong>Antibody-Drug Conjugate (ADC) </strong>:
<ul>
<li>Humanized monoclonal antibody against TAA TROP2 (TACSTD2).</li>
<li>Enzymatically cleavable tetrapeptide-based linker.</li>
<li>Cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951)
derivative DXd (MAAA-1181a; MAAA-1181).</li>
</ul></li>
<li><strong>Mechanism</strong>:
<ul>
<li>Anti-TROP2 antibody targets and binds to TROP2 on tumor cells.</li>
<li>Cellular uptake and lysosomal degradation of the linker.</li>
<li>DXd targets and binds to DNA topoisomerase I.</li>
<li>Stabilizes the cleavable complex between topoisomerase I and
DNA.</li>
<li>Results in DNA breaks, inhibition of DNA replication, and
apoptosis.</li>
<li>Inhibits tumor cell proliferation of TROP2-expressing tumor
cells.</li>
</ul></li>
<li><strong>TROP2 Featuures</strong>:
<ul>
<li>Transmembrane protein overexpressed in various tumors.</li>
<li>Low and/or restricted expression in normal, healthy tissues.</li>
<li>Associated with enhanced tumor aggressiveness, metastasis, drug
resistance, and increased tumor cell survival.</li>
</ul></li>
<li><strong>ADC Advantages</strong>:
<ul>
<li>Reduced systemic exposure.</li>
<li>Enhanced delivery of the cytotoxic agent DXd.</li>
</ul></li>
</ol>
<ul>
<li><a href="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/datopotamab-deruxtecan">NCI
link</a></li>
<li><a href="https://www.daiichisankyo.com/media/press_release/detail/index_3131.html">Daiichi
Sankyo Expands DS-1062 Study to Include Patients with Triple Negative
Breast Cancer; July 02, 2020</a></li>
</ul>
<p><br><br><br><br></p>
</div>
</div>



<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
